African HIV/AIDS trials are more likely to report adequate allocation concealment and random generation than North American trials. by Siegfried, N, Clarke, M, Volmink, J, Van der Merwe, L

GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisp... by Felix, R, Bodmer, W, Fearnhead, N, van der Merwe, L, Goldberg, P, Ramesar, R

GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisp... by Felix, R, Bodmer, W, Fearnhead, N, van der Merwe, L, Goldberg, P, Ramesar, R

GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisp... by Felix, R, Bodmer, W, Fearnhead, N, van der Merwe, L, Goldberg, P, Ramesar, R

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, van der Merwe, L, de Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, Van Der Merwe, L, De Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. by Scriba, T, Tameris, M, Mansoor, N, Smit, E, van der Merwe, L, Isaacs, F, Keyser, A, Moyo, S, Brittain, N, Lawrie, A, Gelderbloem, S, Veldsman, A, Hatherill, M, Hawkridge, A, Hill, A, Hussey, G, Mahomed, H, Mcshane, H, Hanekom, W

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. by Scriba, T, Tameris, M, Mansoor, N, Smit, E, van der Merwe, L, Mauff, K, Hughes, E, Moyo, S, Brittain, N, Lawrie, A, Mulenga, H, de Kock, M, Gelderbloem, S, Veldsman, A, Hatherill, M, Geldenhuys, H, Hill, A, Hussey, G, Mahomed, H, Hanekom, W, Mcshane, H

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. by Scriba, T, Tameris, M, Smit, E, van der Merwe, L, Hughes, E, Kadira, B, Mauff, K, Moyo, S, Brittain, N, Lawrie, A, Mulenga, H, de Kock, M, Makhethe, L, Janse van Rensburg, E, Gelderbloem, S, Veldsman, A, Hatherill, M, Geldenhuys, H, Hill, A, Hawkridge, A, Hussey, G, Hanekom, W, McShane, H, Mahomed, H